You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live



▲  7th Inning 1 outs

Mass. Movers

Bank reaffirms ‘neutral’ rating on Idenix

Idenix aims to develop drugs to treat viral diseases.

Associated Press/File 2012

Idenix aims to develop drugs to treat viral diseases.

Continue reading below

Bank of America reaffirmed its “neutral” rating on shares of Cambridge-based Idenix Pharmaceuticals in a research note released Monday, according to Jags Report. The bank currently has a $7 price target, up from $6. Idenix announced a nonexclusive collaboration with Janssen Pharmaceuticals Inc. for “the clinical development of all-oral direct-acting antiviral HCV combination therapies” — in other words, drug combinations to treat infection with the hepatitis C virus.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of